A Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacology of VTX-2337 When Administered to Adult Subjects With Advanced Solid Tumors or Lymphoma.

Trial Profile

A Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacology of VTX-2337 When Administered to Adult Subjects With Advanced Solid Tumors or Lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 May 2014

At a glance

  • Drugs Motolimod (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors VentiRx Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2011 Results were presented at the 47th Annual Meeting of the American Society of Oncology (ASCO-2011).
    • 21 Dec 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
    • 04 Oct 2010 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top